Blood biomarkers of neuronal injury and glial cell dysfunction and 25‐year cognitive decline and incident dementia in the ARIC study

Abstract

Background: Prospective investigations on blood biomarkers for Alzheimer's disease and related‐dementias (ADRDs) and cognitive impairment provide important insights into their clinical utility in early disease diagnosis and risk stratification, but have been primarily limited to AD pathologies (e.g.